Xtant Medical Stock Price, News & Analysis

Xtant Medical Holdings, a global medical technology company, announced that CEO Sean Browne will present at the Canaccord Musculoskeletal Conference on March 7, 2023, at 3:30 p.m. PT in Las Vegas. The event will be accessible via a live webcast on the company’s website.

A replay of the webcast will be available for approximately 90 days post-presentation. Xtant Medical focuses on surgical solutions for spinal disorders, designing and developing orthobiologics and spinal implant systems for complex spinal procedures.

Xtant Medical Holdings, Inc. (XTNT) announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. Schallenberger, who has over 12 years of experience in orthobiologics, will focus on modernizing production, optimizing operations, and diversifying product lines. President Sean Browne expressed enthusiasm about Schallenberger's role in driving growth. Xtant Medical specializes in surgical solutions for spinal disorders, emphasizing innovation in orthobiologics and spinal implants.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported a 5% increase in third quarter 2022 revenues, reaching $14.5 million, up from $13.8 million in Q3 2021. This growth was driven by a 12% rise in the biologics segment, attributed to the launch of OsteoFactor™ and OsteoVive® Plus products. Gross margin improved to 54.6%, while operating expenses rose to $9.8 million, resulting in a net loss of $2.4 million or $0.03 per share. The company expects to reach full operating capacity by Q1 2023, supported by a recent $9.75 million private placement.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its third-quarter financial results for the period ending September 30, 2022, on November 3, 2022, before market opening. A conference call led by CEO Sean Browne and CFO Scott Neils will follow at 9:00 AM ET to discuss these results. Investors are encouraged to participate via dial-in or web registration, with a replay available thereafter on the company's website.

Xtant Medical focuses on innovative surgical solutions for spinal disorders.

Xtant Medical Holdings (NYSE American: XTNT) announced the conclusion of a second tranche of a private placement, generating approximately $3 million from the sale of around 6.2 million shares and warrants. This follows an earlier tranche which raised approximately $6.75 million from 14.1 million shares and warrants. The total gross proceeds from both transactions are around $9.75 million. The funds will be utilized for working capital and corporate purposes. The Company plans to file a registration statement with the SEC for the resale of the common shares.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced the completion of the first tranche of a private placement, raising approximately $6.75 million by selling about 14.1 million shares and 3.5 million warrants. This financing is expected to enhance the company's growth strategy, as stated by CEO Sean Browne. A second closing tranche, anticipated in early October 2022, is projected to secure an additional $3 million. The company plans to use the funds primarily for working capital and corporate needs.

Xtant Medical Holdings (NYSE American: XTNT) has entered a securities purchase agreement to sell approximately $9.75 million in common stock and warrants to accredited investors, led by Stavros Vizirgianakis, who will become Non-Executive Chairman. The transaction involves the sale of around 20.3 million shares at $0.48 each, with a two-tranche closing process. The first closing is expected on August 26, 2022, with the second planned for October 2022. Proceeds will be used for working capital and corporate purposes. The securities are being offered under SEC exemptions.

Xtant Medical Holdings, Inc. (XTNT) reported a second quarter revenue of $15.3 million, marking a 2% increase year-over-year. The company’s biologics segment showed strong growth, up 8%, driven by new product demand. However, gross margin decreased to 54.8% from 63.5% due to higher costs and inventory charges. The net loss widened to $1.7 million, or $0.02 per share, compared to $0.7 million in Q2 2021. Despite challenges from supply chain issues, Xtant remains optimistic about future growth, with strategic initiatives gaining traction.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) is set to announce its financial results for the second quarter ended June 30, 2022, on August 4, 2022, before market opening. The earnings conference call will occur at 9:00 AM ET, hosted by CEO Sean Browne and CFO Scott Neils. The company specializes in surgical solutions for spinal disorders, focusing on a broad range of orthobiologics and spinal implant systems. Following the call, a replay will be accessible on their website under ‘Investor Info’.